Eli Lilly Moves Forward With Diabetes, Alzheimer's Drugs
26 October 2021 - 10:20PM
Dow Jones News
By Matt Grossman
Eli Lilly & Co. said Tuesday it is proceeding with
regulatory steps to seek approval for drugs to treat type 2
diabetes and Alzheimer's disease.
The Indianapolis-based pharmaceutical company said it has
submitted for review its tirzepatide drug for type 2 diabetes using
a priority-review voucher. Lilly also said it has initiated a
rolling submission of its donanemab drug for Alzheimer's
disease.
Lilly posted third-quarter revenue of $6.77 billion, a rise of
18% from the year-ago quarter. Earnings declined by 8% to $1.22 a
share. Stripping out one-time items, the company's adjusted profit
in the quarter was $1.94 a share.
Lilly said it expects full-year adjusted earnings of $7.95 a
share to $8.05 a share.
Shares climbed 2.2% in pre-market trading.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 26, 2021 07:05 ET (11:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2024 to May 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From May 2023 to May 2024